PubMed Health⌕ Search

Biomedical subjects

K Odegaard

Publications and source records attributed to K Odegaard.

At least 19 recordsLinked to original sources
PubMed2001

Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries.

OBJECTIVE: The primary objective of this study was to estimate the cost effectiveness of treating diabetic foot ulcers with becaplermin (Regranex) plus good wound care (GWC) compared with GWC alone in a variety of European healthcare settings. A secondary objective was to analyse the effect of different treatment practices on the economics of caring for diabetic foot ulcers. DESIGN AND SETTING: Markov-based simulation study from the perspective of a national health system. METHODS: A 12-month Markov computer simulation model was used to assess the cost effectiveness in 4 European countries of treating diabetic foot ulcers with becaplermin plus GWC versus GWC alone. Transition probabilities were taken from a prospective study of 183 patients and becaplermin efficacy was based on 20-week healing rates in a recent meta-analysis of clinical trials involving 449 patients. Country-specific treatment cost data were collected in collaboration with local economic consultations and combined with the disease model to estimate the incremental cost per ulcer-free month gained. The model was then run using hypothetical low- and high-intensity resource usage profiles to investigate the economics of caring for diabetic foot ulcers. RESULTS: Over the course of 1 year, individuals who received becaplermin plus GWC were, on average, predicted to spend an additional 0.81 months (24% longer) free of ulcers and to experience a 9% lower risk of undergoing a lower extremity amputation than individuals who received GWC alone. Consequently, becaplermin plus GWC was estimated to be net cost saving in Sweden, Switzerland and the UK. In France, the addition of becaplermin was estimated to add $US19 (1999 values) for each additional ulcer-free month gained. There were substantial intercountry differences in treatment practices and the costs of treating diabetic foot ulcers. CONCLUSIONS: Becaplermin may be a cost-effective treatment for neuropathic diabetic foot ulcers in a wide range of European settings. In Sweden, Switzerland and the UK, becaplermin may even be cost saving. Substantial intercountry differences in resource patterns appear, at least partly, to be the logical outcome of differences in unit costs.

Becaplermin↗
PubMed1997

Cost of long-term complications of deep venous thrombosis of the lower extremities: an analysis of a defined patient population in Sweden.

BACKGROUND: Little information is available on the epidemiology and economic effect of long-term complications developing after deep venous thrombosis. OBJECTIVE: To determine the extent of, timing of, and treatment costs associated with long-term complications developing after deep venous thrombosis of the lower extremities. DESIGN: 15-year retrospective cohort study. SETTING: County hospital in Sweden. PATIENTS: 257 patients with deep venous thrombosis and 241 age- and sex-matched controls without deep venous thrombosis. MEASUREMENTS: Data on use of health care resources and costs of inpatient and outpatient care, pharmaceutical agents, and treatment of complications. RESULTS: After 15 years of follow-up, 35% of the patients with thrombosis and 57% of the controls were alive. Two hundred forty-two complications were reported among the patients with thrombosis, and 25 similar events were reported among the controls. The average expected present value of the health care cost of treating complications of thrombosis was estimated to be about $4659 in the patients with thrombosis and $375 in the controls. In controls, primary deep venous thrombosis cost about $6000; thus, the additional long-term health care cost of post-thrombotic complications is about 75% of the cost of primary deep venous thrombosis. CONCLUSIONS: The economic effect of post-thrombotic complications is considerable. The use of measures to prevent thromboembolism and its long-term complications are justified on both clinical and economic grounds.

Follow-Up Studies↗
PubMed1995

The economic cost of a streptococcal tonsillitis episode.

OBJECTIVE: To estimate the cost of a streptococcal tonsillitis episode from the data of a questionnaire. SETTING: Five primary health centres in the west of Sweden. PARTICIPANTS: 101 consecutive patients treated for streptococcal tonsillitis. MAIN OUTCOME MEASURE: The cost estimation included costs for physician visit and drug, travel costs to and from the primary health centre, cost of lost production resulting from the patient's or the guardian's absence from work for physician visit or sick-leave, and cost of telephone consultation with a physician or nurse. RESULTS: The period of illness was on average seven days, time to recovery after treatment five days, and the mean period of sick-leave 2.5 days. The total cost of a tonsillitis episode was about SEK 3,300 (385 USD). Of this sum, the cost for the antibiotic accounted for only 3% and loss of production for 75%. CONCLUSION: Differences in the cost of drugs only have a minor influence on the total cost, while factors causing loss of production, such as efficacy and side effects of the drug, have a greater influence. Economic evaluation of pharmaceuticals will be more relevant in the future, and in the search for the most effective treatment, cost effective studies will be integrated with clinical trials.

Adolescent↗
PubMed1982

Improved medium for the transportation of gonococcal specimens.

A modification of Stuart medium, denominated SIFF transport medium, was compared with Stuart (Ringertz's modification), Amies and SBL transport media for its ability to preserve viability of gonococci during transport. The SIFF medium was superior both when using laboratory strains of Neisseria gonorrhoeae and when using clinical specimens. The new transport medium distinguishes itself mainly by an increased osmotic pressure and by its starch content.

Culture Media↗
PubMed1979

Frequency of simultaneous carriage of Neisseria gonorrhoeae and Neisseria meningitidis.

Gonococci were found by culture in 112 of 442 patients suspected of having gonorrhoea. Meningococci were cultured from the pharynx more than twice as often in patients harbouring gonococci (26%) than in patients from whom gonococci could not be cultured (11%). These results could indicate an individual susceptibility to Neisseria organisms or they could be caused by a difference in the behaviour of patients with and without gonorrhoea, the conduct of the former making them not only more likely to be infected with Neisseria gonorrhoeae but possibly more exposed to Neisseria meningitidis as well.

Female↗
PubMed1977

Isolation of Neisseria meningitidis in urogenital/rectal infections.

In 9 cases (6 men, 3 women) during 1975 we have isolated N. meningitidis from routine samples from urogenital/rectal locations to be examined for gonococci by culture. One of the men harboured meningococci in the rectum, the other 5 in the urethra. Two of the women had meningococci in the cervix and one in the urethra. Of the meningococci isolated, one belonged to serogroup A, 6 to group B and 2 to group C. Six of the patients, 4 men and 2 women, who attended the Department of Venereal Diseases, are described in greater detail. Of these, only one had symptoms. The meningococci disappeared spontaneously in 5 cases, whilst a man with unsymptomatic infection still harboured meningococci in the rectum after one month. Two of the 4 men were homosexual.

Adolescent↗
PubMed1976

Isolation of a penicillinase producing strain of Neisseria gonorrhoeae.

A gram-negative diplococcus with the qualifications of a gonococcus was isolated from the urethra of a male infected with gonorrhoea in the Far East. The strain proved to be resistant to penicillin G and ampicillin as judged by the paper disc sensitivity test. The resistance was found to be caused by a powerful production of penicillinase which not only acted on penicillin G and ampicillin, but also on methicillin and partly on cephalosporin (cephalotin) by the test employed.

Ampicillin↗
PubMed1975

Lincomycin in selective medium for the isolation of Neisseria gonorrhoeae.

For the isolation of gonococci, the selective culture medium containing colistin, vancomycin, nystatin and trimethoprim which is usually employed has been changed by substituting lincomycin for vancomycin. The best result was obtained if a concentration of 1/2 mug lincomycin/ml medium was used. This is a concentration of lincomycin considerably lower than that which by other investigators is considered most suitable for the purpose. However, the culture medium used by the latter did not contain trimethoprim. The use of 1/2 mug lincomycin/ml instead of vancomycin 3 mug/ml in the medium caused a slightly more pronounced growth of unwanted organisms. In spite of this, the results obtained by the medium containing lincomycin showed that the number of samples positive for gonococci was 7 per cent higher, and that the number of patients with gonococcal infections to be discovered was 4 per cent higher than the numbers obtained by the medium containing vancomycin. The results were considered highly favourable and, accordingly, by now our laboratory uses 1/2 mug lincomycin/ml medium in the routine isolation of gonococci.

Culture Media↗